Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

PMID:
29298869
2.

Experiences of establishing an academic early phase clinical trials unit.

Brown SR, Sherratt D, Booth G, Brown J, Collinson F, Gregory W, Flanagan L.

Clin Trials. 2017 Aug;14(4):349-356. doi: 10.1177/1740774517710250. Epub 2017 May 22.

PMID:
28532202
4.
5.

Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents.

Young A, Marshall E, Krzyzanowska M, Robinson B, Brown S, Collinson F, Seligmann J, Abbas A, Rees A, Swinson D, Neville-Webbe H, Selby P.

Oncologist. 2016 Mar;21(3):301-7. doi: 10.1634/theoncologist.2014-0341. Epub 2016 Feb 26. Review.

6.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.

7.

Optimal treatment of early-stage ovarian cancer.

Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, Ledermann J, Colombo N, Swart A; ICON1 collaborators.

Ann Oncol. 2014 Jun;25(6):1165-71. doi: 10.1093/annonc/mdu116. Epub 2014 Mar 14.

8.

Biomarkers and response to bevacizumab--response.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Alexandre Z, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann J, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2014 Feb 15;20(4):1058. doi: 10.1158/1078-0432.CCR-13-3269. No abstract available.

9.

Attaining surgical competency and its implications in surgical clinical trial design: a systematic review of the learning curve in laparoscopic and robot-assisted laparoscopic colorectal cancer surgery.

Barrie J, Jayne DG, Wright J, Murray CJ, Collinson FJ, Pavitt SH.

Ann Surg Oncol. 2014 Mar;21(3):829-40. doi: 10.1245/s10434-013-3348-0. Epub 2013 Nov 12. Review.

PMID:
24217787
10.

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann JA, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2013 Sep 15;19(18):5227-39. doi: 10.1158/1078-0432.CCR-13-0489. Epub 2013 Aug 9.

11.

The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer.

Collinson FJ, Gregory WM, McCabe C, Howard H, Lowe C, Potrata D, Tubeuf S, Hanlon P, McParland L, Wah T, Selby PJ, Hewison J, Brown J, Brown J.

BMC Cancer. 2012 Dec 14;12:598. doi: 10.1186/1471-2407-12-598.

12.

Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer.

Green BL, Marshall HC, Collinson F, Quirke P, Guillou P, Jayne DG, Brown JM.

Br J Surg. 2013 Jan;100(1):75-82. doi: 10.1002/bjs.8945. Epub 2012 Nov 6.

13.

Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.

Collinson FJ, Seligmann J, Perren TJ.

Curr Oncol Rep. 2012 Dec;14(6):509-18. doi: 10.1007/s11912-012-0274-4. Review.

PMID:
22948277
14.

A phase 3 trial of bevacizumab in ovarian cancer.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.

N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.

15.

An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer.

Collinson FJ, Jayne DG, Pigazzi A, Tsang C, Barrie JM, Edlin R, Garbett C, Guillou P, Holloway I, Howard H, Marshall H, McCabe C, Pavitt S, Quirke P, Rivers CS, Brown JM.

Int J Colorectal Dis. 2012 Feb;27(2):233-41. doi: 10.1007/s00384-011-1313-6. Epub 2011 Sep 13.

PMID:
21912876
16.

Designing phase II trials in cancer: a systematic review and guidance.

Brown SR, Gregory WM, Twelves CJ, Buyse M, Collinson F, Parmar M, Seymour MT, Brown JM.

Br J Cancer. 2011 Jul 12;105(2):194-9. doi: 10.1038/bjc.2011.235. Epub 2011 Jun 28. Review.

17.

Sunitinib-induced severe hypothyroidism with cardiac compromise.

Collinson FJ, Vasudev NS, Berkin L, Khan MM, Selby PJ, Brown JE.

Med Oncol. 2011 Dec;28 Suppl 1:S699-701. doi: 10.1007/s12032-010-9757-z. Epub 2010 Nov 30.

PMID:
21116874
18.

New therapeutic agents in ovarian cancer.

Collinson F, Jayson G.

Curr Opin Obstet Gynecol. 2009 Feb;21(1):44-53. doi: 10.1097/GCO.0b013e32831ffe71. Review.

PMID:
19125003
19.

Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy.

Collinson FJ, Lam TK, Bruijn WM, de Wilt JH, Lamont M, Thompson JF, Kefford RF.

Ann Surg Oncol. 2008 Jun;15(6):1741-9. doi: 10.1245/s10434-008-9836-y. Epub 2008 Apr 1.

PMID:
18379853
20.

Development of antiangiogenic agents for ovarian cancer.

Collinson FJ, Hall GD, Perren TJ, Jayson GC.

Expert Rev Anticancer Ther. 2008 Jan;8(1):21-32. Review.

PMID:
18095880

Supplemental Content

Loading ...
Support Center